Babson Diagnostics Announces its Scientific Advisory Board

By | Uncategorized | No Comments

AUSTIN, TEXAS, July 30, 2019—Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, has established its Scientific Advisory Board. Drs. Alan Wu, Susan A. Evans, and Robert H. Christenson will join the Babson team as scientific advisors.

Dr. Alan Wu is both a Professor of Laboratory Medicine at UCSF and Chief of Clinical Chemistry and Toxicology Laboratories at San Francisco General Hospital. He was awarded the American Association for Clinical Chemistry Outstanding Contributions to Education Award in 2002, as well as the IVD Technology’s Top Ten Persons in the IVD Industry in 2005. Read More

Babson Diagnostics Wins Austin A-List Award

By | Uncategorized | No Comments

AUSTIN, TEXAS, May 23, 2019—Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, was named a winner at the Greater Austin Chamber of Commerce’s 2019 Austin A-List Awards, “Austin’s premiere honor for homegrown companies.” The A-List honors 24 local companies in various stages of growth that demonstrate cutting-edge innovation, achievable goals, sustainable practices, scalability, and leadership.

“Each nominee and winner represent what makes Austin’s innovative and entrepreneurial community unique and successful. We look forward to a yearlong celebration and relationship with our winners and thank all 165 nominees for everything they do for our community and economy,” said Austin Chamber Senior Vice President, Global Technology and Innovation, Leigh Christie. Read More

Babson Diagnostics Welcomes Mini Kahlon to its Board of Directors

By | Uncategorized | No Comments

AUSTIN, TEXAS, May 14, 2019—Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, welcomed Mini Kahlon as the newest member of its Board of Directors. Regarding her commitment to Babson’s success, Mini expressed, “I believe the space Babson is moving into has significant potential to move the cost and experience curves, and is essential to the vision of delivering healthcare where we live, work, eat, and play.” Read More

Babson Diagnostics Featured in Capital City Innovation Annual Report

By | Uncategorized | No Comments

AUSTIN, TEXAS, March 11, 2019—Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, was featured today in Capital City Innovation’s 2018 Annual Review. Capital City Innovation is a 501(c)(3) nonprofit focused on cultivating collaboration and growth in Austin’s Innovation District, the thriving downtown area that includes UT Austin and Dell Seton Medical Center. In its annual review, Capital City Innovation celebrated Babson Diagnostics as the first graduate of WorkSpaces @ Texas Health CoLab, an Innovation District incubator at UT Austin’s Dell Medical School. This graduation is not only a success for the Babson Diagnostics team, who are now moving into their first clinical laboratory, but also for WorkSpaces and the Innovation District as a whole—a signal that healthcare innovation in Austin is flourishing.

The Capital City Innovation annual report is available at: https://www.capitalcityinnovation.org/s/Austin-innovation-district-annual-review-2018.pdf. Read More

Babson Diagnostics hires Jim Donnelly as Chief Scientific Officer & VP Laboratory Operations

By | Uncategorized | No Comments

AUSTIN, TEXAS, November 5, 2018—Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, has hired Jim Donnelly as its Chief Scientific Officer and Vice President of Laboratory Operations.  Jim will be responsible for the company’s clinical laboratory operations and R&D.

Jim is an accomplished scientific officer in the diagnostics industry.  Jim worked at Siemens Healthineers’ Diagnostics division from 2007-2016, where he served as Chief Scientific Officer and Global VP for the division’s Medical, Clinical, Scientific, and Statistical Affairs groups.  He served as EVP Regulatory and Clinical Affairs for Quotient Limited from 2016-2018. Read More

Babson Diagnostics Secures $3.5 Million in Series A Financing from Prism Ventures

By | Uncategorized | No Comments

AUSTIN, TEXAS, October 19, 2018—Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, secured $3.5 million in Series A financing on October 4 from Prism Ventures, a New York-based advisory and investment firm specializing in life sciences.

Babson Diagnostics is developing a solution that enables retail stores to collect capillary blood at the pharmacy counter for a broad range of routine blood tests. The solution will enable consumers to get laboratory-grade bloodwork done at their trusted local pharmacy—with a short wait time, a fraction of the blood volume, and no hypodermic needle. The solution will enable retailers to expand their healthcare portfolio to include routine blood testing using their existing pharmacy staff and operations. Babson’s approach will accelerate the shift of healthcare services toward retail settings, helping to improve the consumer experience, increase access to preventive medicine, and make healthcare more affordable. Read More

Working to improve our customers’ health by making diagnostic blood testing more convenient, accessible, and human.